Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity
Regulatory T-cells (Tregs) actively engage in the maintenance of immunological self-tolerance and immune homeostasis. The purpose of the present study was to determine how oxaliplatin plus infusional 5-fluorouracil and leucovorin (FOLFOX) and irinotecan plus infusional 5-fluorouracil and leucovorin...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2011-12, Vol.31 (12), p.4569-4574 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4574 |
|---|---|
| container_issue | 12 |
| container_start_page | 4569 |
| container_title | Anticancer research |
| container_volume | 31 |
| creator | MAEDA, Kazunari HAZAMA, Shoichi YOSHINO, Shigefumi OKA, Masaaki TOKUNO, Kazuhisa KAN, Shin MAEDA, Yoshinari WATANABE, Yusaku KAMEI, Ryoji SHINDO, Yoshitaro MAEDA, Noriko YOSHIMURA, Kiyoshi |
| description | Regulatory T-cells (Tregs) actively engage in the maintenance of immunological self-tolerance and immune homeostasis. The purpose of the present study was to determine how oxaliplatin plus infusional 5-fluorouracil and leucovorin (FOLFOX) and irinotecan plus infusional 5-fluorouracil and leucovorin (FOLFIRI) affect Tregs and other immune effectors.
A total of 27 patients with metastatic colorectal cancer received the FOLFOX (n=17) or FOLFIRI (n=10) chemotherapeutic regimen. Blood samples were collected from patients before and 7 days after chemotherapy. The prevalence of Tregs co-expressing CD4(+)FoxP3(+) was analyzed with flow cytometry.
The percentage and the number of CD4(+)FoxP3(+) Tregs were significantly reduced after FOLFOX and FOLFIRI in the patients who had high levels of Tregs before chemotherapy. On the other hand, the total number of lymphocytes and the population of CD4(+) T lymphocytes were unchanged.
FOLFOX and FOLFIRI may enhance antitumor immunity via suppression of Tregs. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_912795482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>912795482</sourcerecordid><originalsourceid>FETCH-LOGICAL-p240t-cf4570801721cde03b0ca3e3176c1b86cdc066cd63232336c6fed06fec22b9dc3</originalsourceid><addsrcrecordid>eNpFkEtLxDAUhYMozjj6FyQbcVXIY5q0Syk-BgYEmVmX9CZ1KklTk3TRf2_AEblw7ua7h3PPBVpTWdNClpxcojVhJSkkIeUK3cT4RYgQdcWv0YoxWtecszU67tykIGHf4-ZknE8nE9S04N4H3Hjrg4GkLG7UCCZgP-IP8zlblXxY8KFojLURq1Hjw-zyxc65eRzScouuemWjuTvvDTq-PB-at2L__rprnvbFxLYkFdBvS0kqQiWjoA3hHQHFDadSAO0qARpyZNCCszxcgOiNJlmAsa7WwDfo8dd3Cv57NjG1boiQQ6nR-Dm2NWWyLrcVy-T9mZw7Z3Q7hcGpsLR_TWTg4QyoCMr2IX88xH-u5JzmAvkPNndnxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>912795482</pqid></control><display><type>article</type><title>Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>MAEDA, Kazunari ; HAZAMA, Shoichi ; YOSHINO, Shigefumi ; OKA, Masaaki ; TOKUNO, Kazuhisa ; KAN, Shin ; MAEDA, Yoshinari ; WATANABE, Yusaku ; KAMEI, Ryoji ; SHINDO, Yoshitaro ; MAEDA, Noriko ; YOSHIMURA, Kiyoshi</creator><creatorcontrib>MAEDA, Kazunari ; HAZAMA, Shoichi ; YOSHINO, Shigefumi ; OKA, Masaaki ; TOKUNO, Kazuhisa ; KAN, Shin ; MAEDA, Yoshinari ; WATANABE, Yusaku ; KAMEI, Ryoji ; SHINDO, Yoshitaro ; MAEDA, Noriko ; YOSHIMURA, Kiyoshi</creatorcontrib><description>Regulatory T-cells (Tregs) actively engage in the maintenance of immunological self-tolerance and immune homeostasis. The purpose of the present study was to determine how oxaliplatin plus infusional 5-fluorouracil and leucovorin (FOLFOX) and irinotecan plus infusional 5-fluorouracil and leucovorin (FOLFIRI) affect Tregs and other immune effectors.
A total of 27 patients with metastatic colorectal cancer received the FOLFOX (n=17) or FOLFIRI (n=10) chemotherapeutic regimen. Blood samples were collected from patients before and 7 days after chemotherapy. The prevalence of Tregs co-expressing CD4(+)FoxP3(+) was analyzed with flow cytometry.
The percentage and the number of CD4(+)FoxP3(+) Tregs were significantly reduced after FOLFOX and FOLFIRI in the patients who had high levels of Tregs before chemotherapy. On the other hand, the total number of lymphocytes and the population of CD4(+) T lymphocytes were unchanged.
FOLFOX and FOLFIRI may enhance antitumor immunity via suppression of Tregs.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 22199332</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; CD4-Positive T-Lymphocytes - immunology ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - immunology ; Female ; Fluorouracil - administration & dosage ; Forkhead Transcription Factors - biosynthesis ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunotherapy - methods ; Leucovorin - administration & dosage ; Male ; Medical sciences ; Middle Aged ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; T-Lymphocytes - immunology ; Tumors</subject><ispartof>Anticancer research, 2011-12, Vol.31 (12), p.4569-4574</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25331006$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22199332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAEDA, Kazunari</creatorcontrib><creatorcontrib>HAZAMA, Shoichi</creatorcontrib><creatorcontrib>YOSHINO, Shigefumi</creatorcontrib><creatorcontrib>OKA, Masaaki</creatorcontrib><creatorcontrib>TOKUNO, Kazuhisa</creatorcontrib><creatorcontrib>KAN, Shin</creatorcontrib><creatorcontrib>MAEDA, Yoshinari</creatorcontrib><creatorcontrib>WATANABE, Yusaku</creatorcontrib><creatorcontrib>KAMEI, Ryoji</creatorcontrib><creatorcontrib>SHINDO, Yoshitaro</creatorcontrib><creatorcontrib>MAEDA, Noriko</creatorcontrib><creatorcontrib>YOSHIMURA, Kiyoshi</creatorcontrib><title>Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Regulatory T-cells (Tregs) actively engage in the maintenance of immunological self-tolerance and immune homeostasis. The purpose of the present study was to determine how oxaliplatin plus infusional 5-fluorouracil and leucovorin (FOLFOX) and irinotecan plus infusional 5-fluorouracil and leucovorin (FOLFIRI) affect Tregs and other immune effectors.
A total of 27 patients with metastatic colorectal cancer received the FOLFOX (n=17) or FOLFIRI (n=10) chemotherapeutic regimen. Blood samples were collected from patients before and 7 days after chemotherapy. The prevalence of Tregs co-expressing CD4(+)FoxP3(+) was analyzed with flow cytometry.
The percentage and the number of CD4(+)FoxP3(+) Tregs were significantly reduced after FOLFOX and FOLFIRI in the patients who had high levels of Tregs before chemotherapy. On the other hand, the total number of lymphocytes and the population of CD4(+) T lymphocytes were unchanged.
FOLFOX and FOLFIRI may enhance antitumor immunity via suppression of Tregs.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - immunology</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Forkhead Transcription Factors - biosynthesis</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Leucovorin - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>T-Lymphocytes - immunology</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLxDAUhYMozjj6FyQbcVXIY5q0Syk-BgYEmVmX9CZ1KklTk3TRf2_AEblw7ua7h3PPBVpTWdNClpxcojVhJSkkIeUK3cT4RYgQdcWv0YoxWtecszU67tykIGHf4-ZknE8nE9S04N4H3Hjrg4GkLG7UCCZgP-IP8zlblXxY8KFojLURq1Hjw-zyxc65eRzScouuemWjuTvvDTq-PB-at2L__rprnvbFxLYkFdBvS0kqQiWjoA3hHQHFDadSAO0qARpyZNCCszxcgOiNJlmAsa7WwDfo8dd3Cv57NjG1boiQQ6nR-Dm2NWWyLrcVy-T9mZw7Z3Q7hcGpsLR_TWTg4QyoCMr2IX88xH-u5JzmAvkPNndnxw</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>MAEDA, Kazunari</creator><creator>HAZAMA, Shoichi</creator><creator>YOSHINO, Shigefumi</creator><creator>OKA, Masaaki</creator><creator>TOKUNO, Kazuhisa</creator><creator>KAN, Shin</creator><creator>MAEDA, Yoshinari</creator><creator>WATANABE, Yusaku</creator><creator>KAMEI, Ryoji</creator><creator>SHINDO, Yoshitaro</creator><creator>MAEDA, Noriko</creator><creator>YOSHIMURA, Kiyoshi</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity</title><author>MAEDA, Kazunari ; HAZAMA, Shoichi ; YOSHINO, Shigefumi ; OKA, Masaaki ; TOKUNO, Kazuhisa ; KAN, Shin ; MAEDA, Yoshinari ; WATANABE, Yusaku ; KAMEI, Ryoji ; SHINDO, Yoshitaro ; MAEDA, Noriko ; YOSHIMURA, Kiyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p240t-cf4570801721cde03b0ca3e3176c1b86cdc066cd63232336c6fed06fec22b9dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - immunology</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Forkhead Transcription Factors - biosynthesis</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Leucovorin - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>T-Lymphocytes - immunology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAEDA, Kazunari</creatorcontrib><creatorcontrib>HAZAMA, Shoichi</creatorcontrib><creatorcontrib>YOSHINO, Shigefumi</creatorcontrib><creatorcontrib>OKA, Masaaki</creatorcontrib><creatorcontrib>TOKUNO, Kazuhisa</creatorcontrib><creatorcontrib>KAN, Shin</creatorcontrib><creatorcontrib>MAEDA, Yoshinari</creatorcontrib><creatorcontrib>WATANABE, Yusaku</creatorcontrib><creatorcontrib>KAMEI, Ryoji</creatorcontrib><creatorcontrib>SHINDO, Yoshitaro</creatorcontrib><creatorcontrib>MAEDA, Noriko</creatorcontrib><creatorcontrib>YOSHIMURA, Kiyoshi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAEDA, Kazunari</au><au>HAZAMA, Shoichi</au><au>YOSHINO, Shigefumi</au><au>OKA, Masaaki</au><au>TOKUNO, Kazuhisa</au><au>KAN, Shin</au><au>MAEDA, Yoshinari</au><au>WATANABE, Yusaku</au><au>KAMEI, Ryoji</au><au>SHINDO, Yoshitaro</au><au>MAEDA, Noriko</au><au>YOSHIMURA, Kiyoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>31</volume><issue>12</issue><spage>4569</spage><epage>4574</epage><pages>4569-4574</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Regulatory T-cells (Tregs) actively engage in the maintenance of immunological self-tolerance and immune homeostasis. The purpose of the present study was to determine how oxaliplatin plus infusional 5-fluorouracil and leucovorin (FOLFOX) and irinotecan plus infusional 5-fluorouracil and leucovorin (FOLFIRI) affect Tregs and other immune effectors.
A total of 27 patients with metastatic colorectal cancer received the FOLFOX (n=17) or FOLFIRI (n=10) chemotherapeutic regimen. Blood samples were collected from patients before and 7 days after chemotherapy. The prevalence of Tregs co-expressing CD4(+)FoxP3(+) was analyzed with flow cytometry.
The percentage and the number of CD4(+)FoxP3(+) Tregs were significantly reduced after FOLFOX and FOLFIRI in the patients who had high levels of Tregs before chemotherapy. On the other hand, the total number of lymphocytes and the population of CD4(+) T lymphocytes were unchanged.
FOLFOX and FOLFIRI may enhance antitumor immunity via suppression of Tregs.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>22199332</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2011-12, Vol.31 (12), p.4569-4574 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_912795482 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences CD4-Positive T-Lymphocytes - immunology Colorectal Neoplasms - drug therapy Colorectal Neoplasms - immunology Female Fluorouracil - administration & dosage Forkhead Transcription Factors - biosynthesis Gastroenterology. Liver. Pancreas. Abdomen Humans Immunotherapy - methods Leucovorin - administration & dosage Male Medical sciences Middle Aged Stomach. Duodenum. Small intestine. Colon. Rectum. Anus T-Lymphocytes - immunology Tumors |
| title | Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T03%3A34%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Chemotherapy%20for%20Colorectal%20Cancer%20on%20Regulatory%20T-Cells%20and%20Tumor%20Immunity&rft.jtitle=Anticancer%20research&rft.au=MAEDA,%20Kazunari&rft.date=2011-12-01&rft.volume=31&rft.issue=12&rft.spage=4569&rft.epage=4574&rft.pages=4569-4574&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E912795482%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=912795482&rft_id=info:pmid/22199332&rfr_iscdi=true |